%0 Journal Article
%T Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.
%A Matt M
%A Duran C
%A Courjon J
%A Lotte R
%A Moing VL
%A Monnin B
%A Pavese P
%A Chavanet P
%A Khatchatourian L
%A Tattevin P
%A Cattoir V
%A Lechiche C
%A Illes G
%A Lacassin-Beller F
%A Senneville E
%A Dinh A
%A  
%J J Glob Antimicrob Resist
%V 25
%N 0
%D 06 2021
%M 33962065
%F 4.349
%R 10.1016/j.jgar.2021.03.026
%X Dalbavancin is a long-lasting lipoglycopeptide active against Gram-positive bacteria, especially methicillin-resistant staphylococci. Few data are available on dalbavancin use for treatment of prosthetic joint infections (PJIs). We describe a cohort of patients treated for PJI with dalbavancin and review the literature regarding this condition.<BR>All adult patients with PJI from the French dalbavancin national cohort from 1 June 2017 to 1 January 2019 were included. We collected clinical and microbiological characteristics and outcome through a standardised questionnaire. Clinical cure was defined as absence of clinical signs of infection at last visit. Failure was a composite criterion defined by persistence or reappearance of signs of infection, and/or switch to suppressive antibiotic treatment and/or death from infection. The literature review was performed using PubMed.<BR>Seventeen patients were included. Bacteria were identified in 16 cases: Staphylococcus aureus (n = 10), including methicillin-resistant S. aureus (n = 1); and coagulase-negative staphylococci (n = 10), including methicillin-resistant Staphylococcus epidermidis (n = 4). Sixteen patients (94.1%) had received antibiotic therapy prior to dalbavancin use (mean of 2.2 ± 1.3 lines). Clinical cure was achieved in 8/17 patients after a median follow-up of 299.0 (IQR 97.0-476.0) days. We reviewed all cases of PJI treated with dalbavancin available in the literature and the overall clinical cure was estimated at 73.1%.<BR>Our study and literature data suggest that use of dalbavancin in PJI could be considered, even as salvage therapy. Dalbavancin appears to be a safe and easy treatment for patients with staphylococcal PJIs.